166 related articles for article (PubMed ID: 33080301)
21. Differential microRNA-34a expression and tumor suppressor function in retinoblastoma cells.
Dalgard CL; Gonzalez M; deNiro JE; O'Brien JM
Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4542-51. PubMed ID: 19443717
[TBL] [Abstract][Full Text] [Related]
22. BRD4 inhibition suppresses cell growth, migration and invasion of salivary adenoid cystic carcinoma.
Wang L; Wu X; Wang R; Yang C; Li Z; Wang C; Zhang F; Yang P
Biol Res; 2017 May; 50(1):19. PubMed ID: 28545522
[TBL] [Abstract][Full Text] [Related]
23. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer.
Jing X; Shao S; Zhang Y; Luo A; Zhao L; Zhang L; Gu S; Zhao X
Exp Cell Res; 2020 Jul; 392(2):112034. PubMed ID: 32339606
[TBL] [Abstract][Full Text] [Related]
24. Targeting bromodomain-containing protein 4 (BRD4) inhibits MYC expression in colorectal cancer cells.
Otto C; Schmidt S; Kastner C; Denk S; Kettler J; Müller N; Germer CT; Wolf E; Gallant P; Wiegering A
Neoplasia; 2019 Nov; 21(11):1110-1120. PubMed ID: 31734632
[TBL] [Abstract][Full Text] [Related]
25. EGFR-mediated signaling pathway influences the sensitivity of oral squamous cell carcinoma to JQ1.
Liu X; Li Q; Huang P; Tong D; Wu H; Zhang F
J Cell Biochem; 2018 Oct; 119(10):8368-8377. PubMed ID: 30687956
[TBL] [Abstract][Full Text] [Related]
26. Co-targeting BET bromodomain BRD4 and RAC1 suppresses growth, stemness and tumorigenesis by disrupting the c-MYC-G9a-FTH1axis and downregulating HDAC1 in molecular subtypes of breast cancer.
Ali A; Shafarin J; Unnikannan H; Al-Jabi N; Jabal RA; Bajbouj K; Muhammad JS; Hamad M
Int J Biol Sci; 2021; 17(15):4474-4492. PubMed ID: 34803511
[TBL] [Abstract][Full Text] [Related]
27. The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition.
Yao W; Yue P; Khuri FR; Sun SY
Oncotarget; 2015 Oct; 6(33):34669-79. PubMed ID: 26415225
[TBL] [Abstract][Full Text] [Related]
28. Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML.
Herrmann H; Blatt K; Shi J; Gleixner KV; Cerny-Reiterer S; Müllauer L; Vakoc CR; Sperr WR; Horny HP; Bradner JE; Zuber J; Valent P
Oncotarget; 2012 Dec; 3(12):1588-99. PubMed ID: 23249862
[TBL] [Abstract][Full Text] [Related]
29. Dysregulation of miR-204-3p Driven by the Viability and Motility of Retinoblastoma via Wnt/β-catenin Pathway In Vitro and In Vivo.
Sun QX; Wang RR; Liu N; Liu C
Pathol Oncol Res; 2020 Jul; 26(3):1549-1558. PubMed ID: 31482398
[TBL] [Abstract][Full Text] [Related]
30. Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma.
Lee DH; Qi J; Bradner JE; Said JW; Doan NB; Forscher C; Yang H; Koeffler HP
Int J Cancer; 2015 May; 136(9):2055-64. PubMed ID: 25307878
[TBL] [Abstract][Full Text] [Related]
31. BET bromodomain inhibitor JQ1 promotes immunogenic cell death in tongue squamous cell carcinoma.
Wang M; Zhao L; Tong D; Yang L; Zhu H; Li Q; Zhang F
Int Immunopharmacol; 2019 Nov; 76():105921. PubMed ID: 31600692
[TBL] [Abstract][Full Text] [Related]
32. JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells.
Zanellato I; Colangelo D; Osella D
Curr Cancer Drug Targets; 2018; 18(8):816-828. PubMed ID: 28669341
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA-129-5p suppresses proliferation, migration and invasion of retinoblastoma cells through PI3K/AKT signaling pathway by targeting PAX6.
Liu Y; Liang G; Wang H; Liu Z
Pathol Res Pract; 2019 Dec; 215(12):152641. PubMed ID: 31727502
[TBL] [Abstract][Full Text] [Related]
34. Interference with the bromodomain epigenome readers drives p21 expression and tumor senescence.
Webber LP; Yujra VQ; Vargas PA; Martins MD; Squarize CH; Castilho RM
Cancer Lett; 2019 Oct; 461():10-20. PubMed ID: 31265875
[TBL] [Abstract][Full Text] [Related]
35. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
[TBL] [Abstract][Full Text] [Related]
36. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of BRD4 Suppresses Cell Proliferation and Induces Apoptosis in Renal Cell Carcinoma.
Wu X; Liu D; Gao X; Xie F; Tao D; Xiao X; Wang L; Jiang G; Zeng F
Cell Physiol Biochem; 2017; 41(5):1947-1956. PubMed ID: 28391274
[TBL] [Abstract][Full Text] [Related]
38. Bromodomain protein BRD4 promotes cell proliferation in skin squamous cell carcinoma.
Xiang T; Bai JY; She C; Yu DJ; Zhou XZ; Zhao TL
Cell Signal; 2018 Jan; 42():106-113. PubMed ID: 29050985
[TBL] [Abstract][Full Text] [Related]
39. JQ1 suppresses tumor growth via PTEN/PI3K/AKT pathway in endometrial cancer.
Qiu H; Li J; Clark LH; Jackson AL; Zhang L; Guo H; Kilgore JE; Gehrig PA; Zhou C; Bae-Jump VL
Oncotarget; 2016 Oct; 7(41):66809-66821. PubMed ID: 27572308
[TBL] [Abstract][Full Text] [Related]
40. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
